2-(2-氯苯基)-2-(4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-基)乙酸甲酯 | 144457-43-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(2-氯苯基)-2-(4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-基)乙酸甲酯
• 英文名称: methyl 2-(2-chlorophenyl)-2-(4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)acetate
• 英文别名: methyl 2-(2-chlorophenyl)-2-(5,7-dihydro-4H-thieno[2,3-c]pyridin-6-yl)acetate
• CAS: 144457-43-2
• 化学式: C₁₆H₁₆ClNO₂S
• 分子量: 321.828
• InChiKey: ZEIGZKQSYIWMTR-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  57.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(2-氯苯基)-2-(4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-基)乙酸甲酯 在 D(+)-10-樟脑磺酸 、 碳酸氢钠 作用下， 以 丙酮 、 二氯甲烷 为溶剂， 以38.7%的产率得到氯吡格雷EP杂质B
  参考文献：
  名称：

  Synthesis and Characterization of Impurity B of S-(+)-Clopidogrel Bisulfate: An Antiplatelet

  摘要：

  S-(+)-Clopidogrel bisulfate [(S-(+)-methyl 2-(2-chlorophenyl)-2-(6, 7-dihydrothieno[3, 2-c]pyridin-5(4H)-yl)acetate bisulfate)] is a platelet aggregation inhibitor drug. S-(+)-Clopidogrel bisulfate is prepared by different synthetic approaches in the literature. In almost all the approaches the major impurities known in the literature (A, B, and C) are also listed in the U.S. pharmacopoeia. The control of these pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. In this article, a description of these impurities and their origins in the S-(+)-clopidogrel bisulfate process are presented along with the preparation of impurity B.

  DOI：

  10.1080/00397911.2011.635393
• 作为产物：
  描述：

  3-氨乙基噻吩 在 盐酸 、 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 6.67h， 生成 2-(2-氯苯基)-2-(4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-基)乙酸甲酯
  参考文献：
  名称：

  Synthesis and Characterization of Impurity B of S-(+)-Clopidogrel Bisulfate: An Antiplatelet

  摘要：

  S-(+)-Clopidogrel bisulfate [(S-(+)-methyl 2-(2-chlorophenyl)-2-(6, 7-dihydrothieno[3, 2-c]pyridin-5(4H)-yl)acetate bisulfate)] is a platelet aggregation inhibitor drug. S-(+)-Clopidogrel bisulfate is prepared by different synthetic approaches in the literature. In almost all the approaches the major impurities known in the literature (A, B, and C) are also listed in the U.S. pharmacopoeia. The control of these pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. In this article, a description of these impurities and their origins in the S-(+)-clopidogrel bisulfate process are presented along with the preparation of impurity B.

  DOI：

  10.1080/00397911.2011.635393

文献信息

• PROCESS FOR PREPARING CLOPIDOGREL
  申请人：Sajja Eswaraiah

  公开号：US20070225320A1

  公开（公告）日：2007-09-27

  A process for preparing clopidogrel or a salt thereof.

  制备氯吡格雷或其盐的方法。
• NEW HPCL METHOD
  申请人：Vijayakumar Erra Koteswara Satya

  公开号：US20110041589A1

  公开（公告）日：2011-02-24

  The present invention relates to new HPLC methods for the analysis of the drug substance clopidogrel and related substances. In a first method the mobile phase comprises two or more liquids, and the relative concentration of the liquids is varied to a predetermined gradient. In a second method the mobile phase comprises a polar protic organic solvent, and the stationary phase comprises a gel. The present invention also relates to a method for analysing a substance, comprising the detection and optional quantification of one or more specific impurities.
• STABLE PHARMACEUTICAL COMPOSITION OF CLOPIDOGREL FREE BASE FOR ORAL AND PARENTERAL DELIVERY
  申请人：Huang Jingjun

  公开号：US20140227360A1

  公开（公告）日：2014-08-14

  The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, m) of 100-500 nm, wherein the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc. The emulsion formulations and method of manufacturing significantly improves the stability of clopidogrel over other aqueous based formulations (such as cyclodextrin-based formulations and emulsion made using clopidogrel salt as the starting materials) with respect to chiral degradation, hydrolytic, and thermal degradation. Ready-to-use emulsion compositions, which can be administered orally or parentally as a single high dose with up to 300 mg of clopidogrel dose, can be prepared and stored at room temperature for at least 19 weeks or at refrigeration temperature for at least 1 year. The compositions will provide rapid therapeutic action as anti-platelet agent for patient under emergence and intense care or who cannot swallow tablet dosage form.
• US9480680B2
  申请人：——

  公开号：US9480680B2

  公开（公告）日：2016-11-01
• US9884016B2
  申请人：——

  公开号：US9884016B2

  公开（公告）日：2018-02-06